- Home
- HRMY vs PLUG Comparison
HRMY vs PLUG Comparison
Compare HRMY & PLUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- PLUG
- Stock Information
- Founded
- HRMY 2017
- PLUG 1997
- Country
- HRMY United States
- PLUG United States
- Employees
- HRMY N/A
- PLUG N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- PLUG Industrial Machinery/Components
- Sector
- HRMY Health Care
- PLUG Energy
- Exchange
- HRMY Nasdaq
- PLUG Nasdaq
- Market Cap
- HRMY 2.1B
- PLUG 2.1B
- IPO Year
- HRMY 2020
- PLUG 1999
- Fundamental
- Price
- HRMY $32.06
- PLUG $2.01
- Analyst Decision
- HRMY Strong Buy
- PLUG Hold
- Analyst Count
- HRMY 9
- PLUG 15
- Target Price
- HRMY $55.33
- PLUG $1.80
- AVG Volume (30 Days)
- HRMY 696.1K
- PLUG 46.7M
- Earning Date
- HRMY 10-28-2025
- PLUG 11-11-2025
- Dividend Yield
- HRMY N/A
- PLUG N/A
- EPS Growth
- HRMY 58.41
- PLUG N/A
- EPS
- HRMY 3.10
- PLUG N/A
- Revenue
- HRMY $772,527,000.00
- PLUG $672,844,000.00
- Revenue This Year
- HRMY $20.09
- PLUG $15.15
- Revenue Next Year
- HRMY $16.86
- PLUG $25.08
- P/E Ratio
- HRMY $10.40
- PLUG N/A
- Revenue Growth
- HRMY 17.74
- PLUG N/A
- 52 Week Low
- HRMY $26.47
- PLUG $0.69
- 52 Week High
- HRMY $41.61
- PLUG $3.32
- Technical
- Relative Strength Index (RSI)
- HRMY 29.47
- PLUG 73.95
- Support Level
- HRMY $31.61
- PLUG $1.41
- Resistance Level
- HRMY $37.05
- PLUG $1.56
- Average True Range (ATR)
- HRMY 1.16
- PLUG 0.10
- MACD
- HRMY -0.56
- PLUG 0.04
- Stochastic Oscillator
- HRMY 6.82
- PLUG 98.36
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.